300267.SZ深圳证券交易所 · 创业板 ChiNext
Hunan Er-Kang Pharmaceutical 尔康制药
Chemical Pharmaceuticals 化学制药
¥3.21+¥0.02 · +0.63%
Open 开盘
¥3.18
High 最高
¥3.25
Low 最低
¥3.14
Prev Close 昨收
¥3.19
Volume 成交量
3,316.8万股
Turnover 成交额
¥1.06亿
Mkt Cap 总市值
¥66亿
P/E 市盈率
−17.8×
Recent Activity 近期动态All Filings 全部公告 →
2 significant filings since 31 May 2026: 1 on major holder selling and 1 on guarantee or financial assistance. The latest, on 22 Jul 2026: 关于控股股东减持计划期限届满的公告. 2 unverified reports logged, the latest on 5 Jun 2026.
自 31 May 2026 起有 2 份重大公告：major holder selling 1 份、guarantee or financial assistance 1 份。最新一份（22 Jul 2026）：关于控股股东减持计划期限届满的公告。记录了 2 条未经核实的报道，最新一条见于 5 Jun 2026。
Price History 价格走势
250 trading days 个交易日 · High 最高 ¥4.84 · Low 最低 ¥2.883.003.504.004.50
Volume 成交量
3.84亿
Sep 25Dec 25Mar 26Jul 26Sep 26
Overview 概览Deep Report 深度报告Financials 财务Valuation 估值Ownership 股东Analysts 券商Estimates 预测News 动态Events 事件Peers 同业
Relative Value 同业比较
Chemical Pharmaceuticals 化学制药 · 158 listed peers
| Measure 指标 | This Company 本公司 | Peer Median 同业中值 | Standing 排位 | |
|---|---|---|---|---|
| Market Cap 市值 | ¥66亿 | ¥63亿 | 78th highest of 158 · 158 家中第 78 高 | |
| Trailing P/E 市盈率 | — | 38.4x | No value 无数据 | |
| P/B 市净率 | 1.6x | 2.5x | 37th lowest of 157 · 157 家中第 37 低 | |
| Revenue Growth 营收增速 | -16.8% | 1.6% | 22nd lowest of 156 · 156 家中第 22 低 | |
| Profit Growth 净利增速 | 18.2% | 1.9% | 62nd highest of 158 · 158 家中第 62 高 | |
| Gross Margin 毛利率 | 31.4% | 50.2% | 40th lowest of 155 · 155 家中第 40 低 | |
| Net Margin 净利率 | 6.0% | 9.8% | 62nd lowest of 157 · 157 家中第 62 低 | |
| Return on Equity 净资产收益率 | 1.1% | 3.1% | 46th lowest of 157 · 157 家中第 46 低 | |
| Debt to Assets 资产负债率 | 20.6% | 28.0% | 52nd lowest of 158 · 158 家中第 52 低 | |
| Grade Score 评级得分 | 31 | 51 | 24th lowest of 157 · 157 家中第 24 低 |
Statement figures are for the period to 30 Jun 2026, filed by 158 of 158 peers. A rank needs 5 or more peers with a value. A company with no earnings has no P/E. 报表数据为截至 30 Jun 2026 的期间，158 家同业中 158 家已披露。排位至少需要 5 家有数据的同业；无盈利的公司没有市盈率。
Largest Peers 主要同业
| Peer 同业 | Market Cap | P/E | P/B | Revenue Growth | Net Margin | ROE | Grade |
|---|---|---|---|---|---|---|---|
| Beone Medicines 百济神州 | ¥3,978亿 | 92.9x | 11.2x | 26.8% | 14.7% | 9.9% | B |
| Hengrui Pharma 恒瑞医药 | ¥2,952亿 | 38.2x | 4.6x | -1.9% | 28.9% | 8.0% | C |
| Haisco Pharmaceutical Group 海思科 | ¥693亿 | 73.0x | 14.1x | 54.7% | 27.5% | 18.3% | B |
| Fosun Pharma 复星医药 | ¥621亿 | 18.3x | 1.3x | 4.8% | 10.5% | 3.5% | D |
| CSPC Innovation Pharmaceutical 石药创新 | ¥618亿 | 60.5x | 15.7x | 208.7% | 47.9% | 38.2% | B |
| Sichuan Kelun Pharmaceutical 科伦药业 | ¥614亿 | 33.6x | 2.5x | -2.7% | 16.1% | 4.6% | C |
| Innocare 诺诚健华 | ¥507亿 | 55.1x | 6.6x | 55.5% | 21.1% | 3.2% | C |
| Allist 艾力斯 | ¥477亿 | 17.8x | 5.6x | 39.9% | 46.4% | 19.7% | B |
| Huadong Medicine 华东医药 | ¥474亿 | 13.7x | 1.9x | 1.8% | 8.3% | 7.3% | C |
| Shenzhen Salubris Pharmaceuticals 信立泰 | ¥333亿 | 49.4x | 3.9x | 16.3% | 15.8% | 4.3% | C |
| Apeloa Pharmaceutical 普洛药业 | ¥311亿 | 36.5x | 4.7x | -11.4% | 10.8% | 8.1% | D |
| Humanwell Healthcare ST人福 | ¥307亿 | 15.1x | 1.6x | -0.0% | 14.0% | 6.8% | C |
| Zelgen 泽璟制药 | ¥284亿 | 51.6x | 16.5x | 220.9% | 53.1% | 45.7% | B |
| Livzon Pharmaceutical Group 丽珠集团 | ¥269亿 | 16.1x | 2.0x | -20.3% | 22.4% | 6.6% | C |
| Hunan Er-Kang Pharmaceutical 尔康制药 | ¥66亿 | — | 1.6x | -16.8% | 6.0% | 1.1% | D |
Peers are listed by market cap, with this company highlighted. 同业按市值排列，本公司高亮显示。